

Online Supplementary Reference List

- [s1] J. Olesen et al., “Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine,” *N. Engl. J. Med.*, vol. 350, no. 11, pp. 1104–1110, 2004.
- [s2] T. W. Ho et al., “Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial,” *Lancet*, vol. 372, no. 9656, pp. 2115–2123, 2008.
- [s3] T. W. Ho et al., “Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine,” *Neurology*, vol. 70, no. 16, pp. 1304–1312, 2008.
- [s4] T. W. Ho et al., “Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention,” *Neurology*, vol. 83, no. 11, pp. 958–66, Sep. 2014.
- [s5] D. J. Hewitt et al., “Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine,” *Cephalalgia*, vol. 31, no. 6, pp. 712–722, 2011.
- [s6] A. Hougaard and P. Tfelt-Hansen, “Review of dose-response curves for acute antimigraine drugs: Triptans, 5-HT_{1F} agonists and CGRP antagonists,” *Expert Opin. Drug Metab. Toxicol.*, vol. 11, no. 9, pp. 1409–1418, 2015.
- [s7] J. Hoffmann and P. J. Goadsby, “New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors,” *Curr. Treat. Options Neurol.*, vol. 14, no. 1, pp. 50–59, 2012.
- [s8] P. R. Holland and P. J. Goadsby, “Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy,” *Neurotherapeutics*, pp. 1–9, 2018.
- [s9] P. J. Goadsby et al., “Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study (S17.001),” *Neurology*, vol. 92, no. 15 Supplement, p. S17.001, Apr. 2019.

- [s10] “Therapeutic Goods Administration (TGA),” 2020. [Online]. Available: <https://www.tga.gov.au/>. [Accessed: 31-Mar-2020].
- [s11] “European Medicines Agency (EMA),” 2020. [Online]. Available: <https://www.ema.europa.eu/en>. [Accessed: 31-Mar-2020].
- [s12] “U.S. Food and Drug Administration (FDA),” 2020. [Online]. Available: <https://www.fda.gov/>. [Accessed: 31-Mar-2020].
- [s13] R. B. Lipton et al., “Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine,” *N. Engl. J. Med.*, vol. 381, no. 2, pp. 142–149, 2019.
- [s14] R. Croop et al., “Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial,” *Lancet (London, England)*, vol. 394, no. 10200, pp. 737–745, 2019.
- [s15] R. Marcus, P. J. Goadsby, D. Dodick, D. Stock, G. Manos, and T. Z. Fischer, “BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial,” *Cephalalgia*, vol. 34, no. 2, pp. 114–25, Feb. 2014.
- [s16] B. Gao et al., “Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials,” *Front. Pharmacol.*, vol. 10, p. 1577, 2019.
- [s17] R. B. Lipton et al., “Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine,” *JAMA*, vol. 322, no. 19, p. 1887, Nov. 2019.
- [s18] J. Ailani et al., “Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial,” *Headache*, vol. 60, no. 1, pp. 141–152, Jan. 2020.
- [s19] “Acute Treatment Trial in Adult Subjects With Migraines,” *ClinicalTrials.gov*, 2020. [Online]. Available: <https://clinicaltrials.gov/ct2/show/NCT03872453>. [Accessed: 25-Aug-2020].

- [s20] D. Kudrow et al., “Eptinezumab for Prevention of Chronic Migraine: Results of 2 Infusions in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy–2) Trial (P2.10-006),” *Neurology*, vol. 92, no. 15 Supplement, p. P2.10-006, Apr. 2019.
- [s21] U. Reuter et al., “Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study,” *Lancet*, vol. 392, no. 10161, pp. 2280–2287, 2018.
- [s22] S. Tepper et al., “Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial,” *Lancet Neurol.*, vol. 16, no. 6, pp. 425–434, 2017.
- [s23] M. Ashina et al., “Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study,” *Cephalalgia*, vol. 38, no. 10, pp. 1611–1621, 2018.
- [s24] S. J. Tepper et al., “Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial,” *Neurology*, vol. 92, no. 20, pp. e2309–e2320, 2019.
- [s25] M. E. Bigal et al., “Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study,” *Lancet Neurol.*, vol. 14, no. 11, pp. 1081–1090, 2015.
- [s26] D. W. Dodick et al., “Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial,” *JAMA*, vol. 319, no. 19, pp. 1999–2008, 2018.
- [s27] M. D. Ferrari et al., “Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a

randomised, double-blind, placebo-controlled, phase 3b trial,” *Lancet*, vol. 6736, no. 19, pp. 1–11, 2019.

[s28] S. D. Silberstein et al., “Fremanezumab for the preventive treatment of chronic migraine,” *N. Engl. J. Med.*, vol. 377, no. 22, pp. 2113–2122, 2017.

[s29] V. Skljarevski, M. Matharu, B. A. Millen, M. H. Ossipov, B.-K. Kim, and J. Y. Yang, “Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial,” *Cephalalgia*, vol. 38, no. 8, pp. 1442–1454, Jul. 2018.

[s30] H. C. Detke, P. J. Goadsby, S. Wang, D. I. Friedman, K. J. Selzler, and S. K. Aurora, “Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study,” *Neurology*, vol. 91, no. 24, pp. E2211–E2221, 2018.

[s31] W. Mulleners et al., “A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: Results from the 3-month double-blind treatment phase of the conquer study,” *J. Neurol. Sci.*, vol. 405, p. 128, Oct. 2019.

[s32] C. L. Bagley et al., “Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine,” *Headache*, vol. 52, no. 3, pp. 409–21, Mar. 2012.

[s33] K. M. Sauro et al., “HIT-6 and MIDAS as measures of headache disability in a headache referral population,” *Headache*, vol. 50, no. 3, pp. 383–95, Mar. 2010.

[s34] J. Hoffmann, “The analysis of calcitonin gene-related peptide – a narrow path between useful and misleading findings,” *Cephalalgia*, p. 033310242094111, Jul. 2020.

[s35] A. Melo-Carrillo et al., “Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats,” *Cephalalgia*, p. 033310241987367, Aug. 2019.

- [s36] A. Melo-Carrillo et al., “Fremanezumab—a humanized monoclonal anti-cgrp antibody—inhibits thinly myelinated (A δ) but not unmyelinated (c) meningeal nociceptors,” *J. Neurosci.*, vol. 37, no. 44, pp. 10587–10596, 2017.
- [s37] M. Armanious, “A retrospective analysis to evaluate the response of the addition of erenumab to onabotulinumtoxinA for the prevention of intractable chronic migraine without aura,” in *American Headache Society 61st Annual Scientific Meeting*, 2019.
- [s38] S. Sacco et al., “European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention,” *J. Headache Pain*, vol. 20, no. 1, p. 6, Dec. 2019.
- [s39] L. Lassen, P. Haderslev, V. Jacobsen, H. Iversen, B. Sperling, and J. Olesen, “Cgrp May Play A Causative Role in Migraine,” *Cephalalgia*, vol. 22, no. 1, pp. 54–61, Feb. 2002.
- [s40] J. M. Hansen, L. L. Thomsen, J. Olesen, and M. Ashina, “Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype,” *Neurology*, vol. 71, no. 11, pp. 841–847, Sep. 2008.
- [s41] C. A. Meskunas, S. J. Tepper, A. M. Rapoport, F. D. Sheftell, and M. E. Bigal, “Medications Associated with Probable Medication Overuse Headache Reported in a Tertiary Care Headache Center Over a 15-Year Period. CME,” *Headache J. Head Face Pain*, vol. 46, no. 5, pp. 766–772, May 2006.
- [s42] D. W. Dodick et al., “OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program,” *Headache*, vol. 50, no. 6, pp. 921–936, 2010.
- [s43] A. Negro, M. Curto, L. Lionetto, D. Crialesi, and P. Martelletti, “OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study,” *Springerplus*, vol. 4, no. 1, pp. 1–8, 2015.

- [s44] M. De Felice and F. Porreca, "Opiate-induced persistent pronociceptive trigeminal neural adaptations: Potential relevance to opiate-induced medication overuse headache," *Cephalalgia*, vol. 29, no. 12. NIH Public Access, pp. 1277–1284, Dec-2009.
- [s45] S. Gupta, S. J. Nahas, and B. L. Peterlin, "Chemical Mediators of Migraine: Preclinical and Clinical Observations," *Headache J. Head Face Pain*, vol. 51, no. 6, pp. 1029–1045, Jun. 2011.
- [s46] C. S. Walker, D. L. Hay, and D. L. Hay, "Themed Section: Neuropeptides REVIEW CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?," 2013.
- [s47] W. S. Schou, S. Ashina, F. M. Amin, P. J. Goadsby, and M. Ashina, "Calcitonin gene-related peptide and pain: a systematic review," *J. Headache Pain*, vol. 18, no. 1, 2017.
- [s48] P. J. Goadsby, L. Edvinsson, and R. Ekman, "Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system," *Ann. Neurol.*, vol. 23, no. 2, pp. 193–196, Feb. 1988.
- [s49] Z.-L. Qin et al., "Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia," *Clin. Neurol. Neurosurg.*, vol. 143, pp. 111–115, 2016.
- [s50] A. Melo-Carrillo et al., "Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody.," *J. Neurosci.*, vol. 37, no. 30, pp. 7149–7163, Jun. 2017.
- [s51] A. Melo-Carrillo et al., "Fremanezumab-a humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (A δ) but not unmyelinated (C) meningeal nociceptors," Cite as *J. Neurosci*, 2017.
- [s52] S. K. Sauer, G. M. Bove, B. Averbeck, and P. W. Reeh, "Rat peripheral nerve components release calcitonin gene-related peptide and prostaglandin E2 in response to

noxious stimuli: evidence that nervi nervorum are nociceptors,” *Neuroscience*, vol. 92, no. 1, pp. 319–325, Aug. 1999.

[s53] K. Messlinger, J. K. Lennerz, M. Eberhardt, and M. J. M. Fischer, “CGRP and NO in the Trigeminal System: Mechanisms and Role in Headache Generation,” *Headache J. Head Face Pain*, vol. 52, no. 9, pp. 1411–1427, Oct. 2012.

[s54] P. J. Goadsby and L. Edvinsson, “Human in vivo evidence for trigeminovascular activation in cluster headache Neuropeptide changes and effects of acute attacks therapies,” *Brain*, vol. 117, no. 3, pp. 427–434, 1994.

[s55] A. Carmine Belin, C. Ran, and L. Edvinsson, “Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache,” *Brain Sci.*, vol. 10, no. 1, p. 30, Jan. 2020.

[s56] A. L. H. Vollesen et al., “Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks,” *JAMA Neurol.*, vol. 75, no. 10, p. 1187, Oct. 2018.

[s57] P. J. Goadsby et al., “Trial of galcanezumab in prevention of episodic cluster headache,” *N. Engl. J. Med.*, vol. 381, no. 2, pp. 132–141, 2019.

[s58] D. W. Dodick et al., “Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment,” *Cephalalgia*, p. 333102420905321, Feb. 2020.

[s59] A. Snoer et al., “Calcitonin-gene related peptide and disease activity in cluster headache,” *Cephalalgia*, vol. 39, no. 5, pp. 575–584, 2019.

[s60] Amgen, “Aimovig Product Information.” 2019.

[s61] P. R. R. Gangula, Y. L. Dong, S. J. Wimalawansa, and C. Yallampalli, “Infusion of Pregnant Rats with Calcitonin Gene-Related Peptide (CGRP)8-37, a CGRP Receptor Antagonist, Increases Blood Pressure and Fetal Mortality and Decreases Fetal Growth1,” *Biol. Reprod.*, vol. 67, no. 2, pp. 624–629, Aug. 2002.

[s62] European Medicines Agency, “Aimovig Assessment Report,” 2018.

- [s63] P. J. Goadsby et al., “A Controlled Trial of Erenumab for Episodic Migraine,” *N. Engl. J. Med.*, vol. 377, no. 22, pp. 2123–2132, 2017.
- [s64] D. W. Dodick et al., “Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial,” *Lancet Neurol.*, vol. 13, no. 11, pp. 1100–1107, 2014.
- [s65] S. Tanveer and U. States, “MTIS 2018 Abstracts,” *Cephalalgia*, vol. 38, no. 1, pp. 1–115, 2018.
- [s66] L. R.B. et al., “A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine: Results of the PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Effi,” *Neurology*, vol. 90, no. 24, pp. e2193–e2194, 2018.
- [s67] H. Sun et al., “Safety and efficacy of AMG 334 for prevention of episodic migraine: A randomised, double-blind, placebo-controlled, phase 2 trial,” *Lancet Neurol.*, vol. 15, no. 4, pp. 382–390, 2016.
- [s68] D. W. Dodick, P. J. Goadsby, E. L. H. Spierings, J. C. Scherer, S. P. Sweeney, and D. S. Grayzel, “Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomised, double-blind, placebo-controlled study,” *Lancet Neurol.*, vol. 13, no. 9, pp. 885–892, 2014.
- [s69] S. Förderreuther, Q. Zhang, V. L. Stauffer, S. K. Aurora, and M. J. A. Láinez, “Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: Data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies,” *J. Headache Pain*, vol. 19, no. 1, 2018.
- [s70] D. D. Ruff et al., “Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure,” *Cephalalgia*, vol. 39, no. 8, pp. 931–944, 2019.

[s71] R. Lipton, P. Desai, S. Sapra, D. Buse, K. Fanning, and M. Reed, “How much change in head-ache-related disability is clinically meaningful? Estimating minimally important difference (MID) or change in MIDAS using data from the AMPP study. Poster PF52,” *Headache J. Head Face Pain*, vol. 52, no. 3, pp. 165–166, 2017.

[s72] A. F. H. Smelt, W. J. J. Assendelft, C. B. Terwee, M. D. Ferrari, and J. W. Blom, “What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients.,” *Cephalalgia*, vol. 34, no. 1, pp. 29–36, Jan. 2014.

[s73] A. Kawata et al., “Development of a Responder Definition for the Migraine Physical Function Impact Diary (MPFID),” *Value Heal.*, vol. 19, no. 7, p. A383, Nov. 2016.